On September 30, HBM HOLDINGS-B rose 5.1% in regular trading, trading at HK$14.23/share, with turnover of approximately HK$40.48 million. The stock continued to benefit from a cluster of recent positive developments.

On the news front, the company's wholly-owned subsidiary Nona Biosciences successfully developed HCAbLM, the world's first language model trained on fully human heavy-chain-only antibodies. The model captures unique sequence grammar patterns specific to heavy-chain-only antibody formats that conventional antibody language models fail to capture, marking a significant milestone in AI-driven antibody discovery.

Additionally, the company reported H1 revenue of US$122 million, up 20.9% year-over-year, with gross margin reaching 95.24%. Molecule licensing and collaboration revenue rose to US$113 million, while research services and technology licensing fees grew 23.8% to US$9.4 million. The company's partner Solstice Oncology also completed a US$225 million Series A financing, and its TSLP-targeting antibody HBM9378/WIN378 delivered positive Phase II interim results in asthma with Phase III already underway. The stock was also recently included in the Stock Connect program, broadening its investor base.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)